Investor Dashboard
Key financial KPIs at a glance — % against revenues in QuickBooks-statement style.
Revenue Mix · % of Top Line
Cost Structure · % of Operating Cost
Use of Funds · % of $3.5M Raise
Problem & Solution
Capturing the sustainable-protein shift in a $3.23B Canadian market by 2030
The Problem
Canadian pet food ingredient supply is constrained by scarcity of premium meats, specialty grains, and certified-organic raw materials. Rising raw-material costs hinder formulation innovation. Pet ownership is growing (81.9% urbanization, rising disposable income) but the supply chain has not modernized to deliver novel proteins, traceable sourcing, or personalized nutrition at scale.
Our Solution
A vertically integrated ingredient platform combining (1) novel sustainable proteins (insect protein from black-soldier-fly and silkworm, egg-derived protein, plant-based options), (2) traceable conventional protein sourcing (beef, chicken, fish), and (3) certified-organic SKUs. Distribution covers offline retail, online direct, marketplaces, and subscription services.
Market Opportunity
$2.11B → $3.23B addressable today
5.9% CAGR · volume 379kt → 469.79kt (2.7% volume CAGR) by 2030
Wholesale ingredient supply to pet-food manufacturers (60%), direct-to-brand premium SKU programs (25%), and subscription/repeat-order programs for small-batch artisan brands (15%). Dog-food ingredients are the largest segment; cat-food premium tier is the fastest-growing.
Financial Statements · % vs Revenue
QuickBooks-style readout — every line shown as percentage of its parent total.
Revenue Mix
| Revenue Stream | % of Revenue | Share |
|---|---|---|
| Conventional Proteins | 55.0% | 55% |
| Vegan / Plant-Based | 18.0% | 18% |
| Novel Proteins (Insect / Egg) | 12.0% | 12% |
| Certified-Organic SKUs | 10.0% | 10% |
| Personalized Nutrition | 5.0% | 5% |
| Total Revenue | 100.0% | 100% |
Cost Structure
| Cost Line | % of Cost | Share |
|---|---|---|
| Raw Material / Protein Sourcing | 60.0% | 60% |
| Processing & Co-Packing | 12.0% | 12% |
| Logistics & Cold Chain | 10.0% | 10% |
| Sales & Account Mgmt | 8.0% | 8% |
| R&D / Formulation | 5.0% | 5% |
| G&A & Compliance | 5.0% | 5% |
| Total Operating Cost | 100.0% | 100% |
Use of Funds — $3.5M Raise
| Allocation | % of Raise | Share |
|---|---|---|
| Novel-Protein Supply Lock-Up | 35.0% | 35% |
| Processing & Co-Pack Capacity | 25.0% | 25% |
| Sales Team & Brand Accounts | 20.0% | 20% |
| R&D / Formulation | 10.0% | 10% |
| Working Capital | 10.0% | 10% |
| Total Use of Funds | 100.0% | 100% |
Valuation, Capital Structure & Forward View
An investment is a bet on the forward plan, so a trailing snapshot isn't enough. These are derived from this report's own ask and projections — not external estimates.
Capital Structure & Funding
An equity round with no structural debt disclosed — capital-structure risk is dilution and runway rather than credit or covenants. Any future expansion or working-capital debt would change this profile and should be tracked.
How to read these
Rule of 40 sums forward revenue growth and EBITDA margin — ≥40 is healthy; below it flags growth bought at the cost of profit. Capital efficiency is Year-5 revenue per dollar raised. Entry multiple divides the disclosed cap / pre-money / asking price by Year-3 revenue, shown only where disclosed (n/d = not derivable). Verify against primary diligence.
Traction & Proof Points
- Active supply relationships with novel-protein producers (BSFL, silkworm) and conventional protein partners
- Distribution coverage across 4 channels — offline retail, online direct, marketplaces, subscription
- Multi-pet-segment SKU coverage with dog as primary revenue driver
Moat & Exit Strategy
Defensible Moat
Locked-in novel-protein supply contracts at a moment when ingredient scarcity is the industry's defining constraint. Multi-channel distribution combined with certified-organic capability creates a single counterparty for premium pet-food brands. US-tariff mitigation via domestic sourcing alternatives is a competitive shield as protectionism rises.
Exit Path
Strategic sale to a global ingredients leader (ADM, Cargill, Symrise, BASF) or pet-food incumbent seeking novel-protein and traceability capabilities, within 5–7 years.
Key Risks
- US-tariff exposure on imported ingredients (high severity per Porter's analysis)
- Premium ingredient scarcity driving raw-material cost inflation
- Regulatory complexity around novel-protein approvals (insect-based feed)
When the Thesis Breaks
Read this before trusting the forward numbers. The case rests on operating leverage — revenue growth converting into a holding-or-expanding EBITDA margin. The fastest way it breaks: a period where revenue grows but EBITDA falls (margin compression).
If any of the Key Risks above materialise, the forward projections in this report should be treated as suspended until the model is re-underwritten. The single most material trigger to watch: US-tariff exposure on imported ingredients (high severity per Porter's analysis).